1 / 70

Drugs Used for Hypertension

Drugs Used for Hypertension. Philip Marcus, MD MPH. Hypertension: Epidemiology. Elevation in Blood Pressure High Prevalence in US population Affects up to 24% of adults Over 50 million people affected in US Untreated in a large percentage Only 53% treated

ariane
Download Presentation

Drugs Used for Hypertension

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Drugs Used for Hypertension Philip Marcus, MD MPH

  2. Hypertension: Epidemiology • Elevation in Blood Pressure • High Prevalence in US population • Affects up to 24% of adults • Over 50 million people affected in US • Untreated in a large percentage • Only 53% treated • Lack of treatment may result in irreversible damage

  3. Primary (Essential) Hypertension: • No identifiable cause • Accounts for 95%+/- of cases • Clusters in families • Chronic and progressive • Populations at risk: • Elderly • Postmenopausal females • African-Americans • Obese • Drug therapy lowers BP • Does not eliminate underlying pathology • Treatment generally lifelong • Smoking and Obesity are cofactors

  4. Primary Hypertension: Pathophysiology • Increased sympathetic activity • Increased production of sodium retaining hormones and vasoconstrictors • Long term sodium intake • Inadequate potassium/calcium intake • Increased renin secretion • Deficiency of endogenous vasodilators • Prostaglandin, Prostacyclin • Nitric Oxide • Obesity and Insulin resistance

  5. Classification of Hypertension:

  6. Secondary Hypertension: • Chronic Renal Disease 4% • Renovascular Disease 2% • Coarctation of Aorta 0.3% • Primary Aldosteronism 0.2% • Cushing’s Syndrome 0.1% • Oral Contraceptive Use 1% • Pheochromocytoma 0.1% • Sleep Apnea • 50% have significant hypertension

  7. Consequences of Hypertension: • Untreated hypertension leads to increase in morbidity and mortality • Heart Disease • LV Hypertrophy and Congestive Heart Failure • Coronary Artery Disease • Renal Disease • Increased prevalence despite available treatment • Retinal Disease • Cerebral Vascular Disease • Stroke

  8. Benefits of Antihypertensive Treatment • Greater in elderly than in younger patients over short term (5 years) • Older persons at higher immediate and absolute risk of developing cardiovascular events • Prevalence of preexisting cardiovascular disease greater • Systolic hypertension is associated with greater cardiovascular risk than diastolic • Systolic hypertension more prevalent in elderly • Smoking less common in older persons • Smokers respond less well to antihypertensive treatment • Most large trials involving elderly are more recent than those involving younger patients • Use treatment regimens with fewer adverse effects • Benefits of therapy increase over time • Long-term benefits may be greater in younger patients

  9. Non-Drug Management of Hypertension: Lifestyle Modification • Weight reduction • Sodium restriction • Alcohol restriction • Smoking cessation • Exercise • Maintenance of dietary potassium(>100 mEq/day) and calcium intake • Dietary Approaches to Stop Hypertension (DASH) • Reductions in BP in persons on diet rich in fruits, vegetables, and low-fat dairy products • Lowered BP in all subgroups • Appel, et al, NEJM 1997; 336:1117

  10. Physiologic Control of Blood Pressure • BP = C.O. x SVR • C.O. = H.R. x Stroke Volume • Factors to be considered: • Heart Rate • Blood Volume • Contractility • Arteriolar Constriction

  11. HR x SV Arterial Pressure Cardiac Output Peripheral Resistance = X 1. Heart Rate 2. Contractility 3. Blood Volume 4. Venous Return Arteriolar Constriction

  12. Mechanisms Regulating Blood Pressure: • Sympathetic Nervous System • Baroreceptors • Medullary vasomotor center • Renin Angiotensin System • Angiotensinogen • a-2 globulin • Activated by Renin • Produced by JG cells • Increased by decreased renal blood flow • Increased with b-1 stimulation • Observed clinically with renal artery stenosis, hypotension

  13. Mechanisms Regulating Blood Pressure: • Renin Angiotensin System • Angiotensin I • Product of renin action on angiotensinogen • Converted by Angiotensin-Converting Enzyme • Primarily in vasculature and lung • Angiotensin II • Acts on Angiotensin Receptors (AT1) • Causes vasoconstriction • Causes release of Aldosterone • Converted to Angiotensin III in adrenal • Aldosterone • Results in Na retention and K loss • Expands extracellular fluid volume • Action of Angiotensin II and Aldosterone results in decrease in renin secretion

  14. Sites of Antihypertensive Drug Action • Central Nervous System • Vasomotor center • Suppresses sympathetic outflow • Cardiac • Resistance Vessels (arterioles) • Results in: • Reduction in Heart Rate • Decrease in Contractility • Vasodilatation • Typical drugs: • Clonidine, • Methyldopa

  15. Sites of Antihypertensive Drug Action • Sympathetic Ganglia • Ganglionic blockade reduces sympathetic stimulation to heart and blood vessels • Cause vasodilatation and reduction in HR • Rarely used anymore • Trimethaphan last remaining agent • Adrenergic Nerve Terminals • Decreases NE release • Results in decreased stimulation of heart and blood vessels • Guanethidine, reserpine

  16. Sites of Antihypertensive Drug Action • Cardiac b-1 Receptors • Results in decrease in HR and contractility • Vascular a-1 Receptors • Results in vasodilatation • Prazosin, Terazosin, Labetalol • SA node and myocardium • Calcium channel blockers • Verapamil and Diltiazem • Renal tubules • Diuretic agents • Furosemide, Hydrochlorothiazide

  17. Diuretics Used in the Treatment of Hypertension

  18. Sites of Antihypertensive Drug Action • b-1 Receptors on juxtaglomerular cells • Reduces renin release • Vascular Smooth Muscle • Direct vasodilators • Hydralazine • Angiotensin-Converting Enzyme Inhibitors • Decreases formation on Angiotensin II • Captopril, Enalapril • Angiotensin II Receptor Blockers • Results in blockade of AT1 receptors • Losartan, Candesartan • Similar in action to ACE inhibitors • D1 (dopamine) Receptor Agonists

  19. Hypertensive Crisis: • Severe Increase in BP • Diastolic BP > 120 • Rate of rise more important than absolute BP in determining need for EMERGENCYtreatment • Usually occurs in noncompliant or under-medicated patients • In absence of evidence of acute or ongoing target organ damage, no need for acute, aggressive BP reduction

  20. Hypertensive Crisis: What constitutes the Hypertensive Emergency? • Encephalopathy • Myocardial Infarction or Unstable Angina • Congestive Heart Failure • Subarachnoid hemorrhage, stroke or intracerebral hemorrhage • Dissecting Aortic Aneurysm • Cocaine overdose • Acute renal insufficiency • Post-operative hypertension

  21. Centrally Acting Antiadrenergic Agents: • Act in CNS to reduce firing of sympathetic neurons • Effects are the result of decreased stimulation of a & b receptors in periphery • Stimulate central inhibitory a-2 receptors • Acts on post-synaptic receptors • Exerts inhibitory influence on regions of brain that regulate sympathetic nervous activity • Primary site of action in medulla

  22. Centrally Acting Antiadrenergic Agents: • Clonidine (Catapres ®) • 2-imidazoline derivative • Results in decrease in BP, HR and CO • Decreases renal vascular resistance • Renal blood flow unchanged • Lipid soluble • Enters CNS • Side effects common • Dry mouth, dizziness, drowsiness • Gynecomastia, rebound hypertension • Oral and Transdermal route • Also used in drug, alcohol and nicotine withdrawal

  23. Centrally Acting Antiadrenergic Agents: • Clonidine HCl • Recently introduced in epidural form • Useful in this formulation for neuropathic pain • Primarily used in patients with neoplastic disease • Produces analgesia at presynaptic and postjunctional a-2 adrenergic receptors in the spinal cord • Prevents pain signal transmission to the brain • Pain relief additive to morphine • Duraclon ™

  24. Centrally Acting Antiadrenergic Agents: • Methyldopa (Aldomet ®) • Analog of L-dopa • Action similar to clonidine • Requires uptake into CNS neurons • Converted to methyl-norepinephrine • Results in decrease in BP with little cardiac effects • Large 1st pass effect • Low bioavailability • Oral and IV administration • Side Effects • Positive Coomb’s test, Hemolytic Anemia • Hepatotoxicity • Sedation, Lactation

  25. Adrenergic Neuron Blocking Agents: • Act in presynaptic location to reduce NE release from sympathetic neurons • Rarely used in therapy because of side effects • Previously major agents used in treatment • Reserpine and Guanethidine

  26. Rauwolfia serpentina

  27. Reserpine • Rauwolfia alkaloid • Causes depletion of NE from postganglionic sympathetic neurons • Decreases stimulation of all adrenergic receptors • Effects resemble a + b blockade • Blocks uptake of dopamine into vesicles which prevents NE synthesis • Interferes with ATP and Mg++ dependent uptake • Displaces NE from vesicles causing degradation of NE by MAO • Acts peripherally and in CNS

  28. Reserpine • Physiologic Effects • Bradycardia • Decreased Cardiac Output • Vasodilatation • End result is reduction in Blood Pressure • Side Effects • Sedation and Depression • Nasal stuffiness • Orthostatic hypotension • Extrapyramidal effects • GI hypersecretion • Diarrhea, cramps, Increased gastric Acid

  29. Guanethidine • Acts presynaptically to inhibit the release of NE from sympathetic neurons • Must first be taken up into terminals of sympathetic nerves • Uptake via active transport for NE • After uptake, will prevent further NE release • Can promote NE release initially • Polar compound • Highly basic Nitrogen • Does NOT enter CNS • Oral route, t1/2 = 5 days

  30. Guanethidine • Physiologic Effects • Bradycardia • Decreased Cardiac Output • Vasodilatation • Side Effects • Resemble those of pharmacologic sympathectomy • Orthostatic Hypotension • Diarrhea • Defective ejaculation • Effects decreased by compounds that interfere with uptake • Tricyclic Antidepressants • Cocaine • Phenothiazine drugs

  31. a-1 Adrenergic Blockers: • Useful in hypertension and pheochromocytoma • Selective inhibitors of a-1 receptor • Contrast with phenoxybenzamine and phentolamine • Cause blockade of a-1 & a-2 receptors • Used also for urinary obstruction in BPH • Alternative to surgery • Results in decrease in tone in smooth muscle of bladder neck and prostate • Improves urine flow

  32. a-1 Adrenergic Blockers: • Physiologic Effects: • Decrease peripheral vascular resistance • Relax arterial and venous smooth muscle • Results in decrease in Blood Pressure • Minimal changes in Cardiac Output, renal blood flow and GFR • Used orally

  33. a-1 Adrenergic Blockers: • Side Effects • Orthostatic Hypotension • Results from blockade of venous a receptors causing pooling when upright • Reflex tachycardia, generally not long-term • Nasal Congestion • Impotence • Interference with ejaculation • Sodium retention and edema • Frequently used with a diuretic • First-dose effect • Exaggerated hypotensive effect • Results in syncope • Adjust first dose to 1/3 to ¼ usual dose at bedtime

  34. a-1 Adrenergic Blockers: • Prazosin (Minipress ®) • Initial agent • Short half-life • Terazosin (Hytrin ®) • Longer acting • Half-life = 12 hours • Doxazosin (Cardura ®) • Longest half-life, 20 hours Tamsulosin: Flomax®

  35. Vasodilators: • Direct Vasodilators • Hydralazine • Minoxidil • Angiotensin-Converting Enzyme Inhibitors • Angiotensin II Receptor Blockers

  36. Vasodilators: • Traditionally not used as primary drugs for hypertension • Produce relaxation of vascular smooth muscle, predominantly arteriolar • Decreases SVR • Decreases Blood Pressure • Result in reflex tachycardia and increased contractility • May precipitate angina • Increase myocardial oxygen consumption • Also result in increase in plasma renin concentration • Sodium and water retention

  37. Hydralazine (Apresoline ®) • Hydrazine derivative • Direct arteriolar smooth muscle dilator • Rapidly and almost totally absorbed from GI tract • Significant 1st-pass effect • Peak levels in ½ to 2 hours • Correlates with peak hypotensive effects • t-1/2 2-4 hours, duration of action 6-8 hours • Acetylation • Slow vs. Fast acetylators • 87% protein-bound

  38. Hydralazine (Apresoline ®) • Side Effects: • Headache • Nausea, vomiting • Tachycardia, dizziness • Fluid retention • Lupus syndrome • Occurs in up to 10% of patients • Generally with >400 mg/day • Generally reversible upon discontinuation

  39. Minoxidil: • Selective arteriolar dilator • ? Effect on opening of K channels • Antagonizes action of intracellular cAMP on K channels • Opens K channels causing relaxation of muscle • No effect on capacitance vessels (veins) • Rapidly and completely absorbed • Extensive metabolism • Eliminated in urine • Hypertrichosis • Occurs in 80% receiving drug > 4 weeks • Used topically to stimulate hair growth (Rogaine®) • Reserved for use in severe hypertension

  40. Sodium Nitroprusside (Nipride ®): • Causes arterial and venous smooth muscle relaxation • Decreases preload and afterload • Action more pronounced in upright patient • Increased venous pooling occurs • Renal blood flow and GFR maintained • Increased plasma renin activity • No tachycardia occurs • Mechanism similar to nitrates • Results in increase in cGMP

  41. Sodium Nitroprusside

  42. Sodium Nitroprusside (Nipride ®): • Used exclusively via intravenous infusion • Onset of action with 1 to 2 minutes • t1/2 of minutes • Used for hypertensive emergencies and severe CHF • Used also for aortic dissection

  43. Sodium Nitroprusside (Nipride ®): • Fe++ reacts with –SH compounds in RBC • CN- produced • Reduced to SCN- in liver (rhodanase) • Sodium thiosulfate (S donor) facilitates metabolism of CN- • Hydroxy-cobalamin also combines with CN-(cyanocobalamin) • SCN- excreted in urine • Half-life 3 to 4 days • May accumulate after prolonged use • Causes toxic psychosis • Predisposing factors include renal disease and hyponatremia • Monitor levels >3 days [0.1 mg/ml] • Acute toxicity • Excess vasodilatation and hypotension

  44. Diazoxide • Thiazide compound • No diuretic effect • Selective arteriolar dilator • Results in decrease in SVR and BP • Compensatory increase in HR and contractility • Increase Na and water retention • Pharmacokinetics • Administer via bolus IV injection • Extensively bound to albumin • Effects in minutes, half-life = 24 hours • Adverse Effects • Hyperglycemia • Suppresses insulin release • Hyperuricemia • Decreases renal uric acid excretion

More Related